Objectives Pulmonary thrombus formation is a hallmark of coronavirus disease 2019
(COVID-19). A dysregulated immune response culminating in thromboinflammation has …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread all over the world
immediately after the first patient infected with this virus was discovered in Wuhan, China, in …

Severe COVID-19 infections present with cytokine storms, hypercoagulation, and acute
respiratory distress syndrome, with extracellular vesicles (EVs) being involved in …

Abstract Background Infection by SARS‐CoV‐2 produces significant pulmonary pathology
including endothelial damage with resultant thrombotic events. While pathologic features …

Background: Severe acute respiratory syndrome corona virus 2 infection causes severe
pneumonia (coronavirus disease 2019 [COVID-19]), but the mechanisms of subsequent …

Background Severe acute respiratory syndrome coronavirus 2 infection is associated with
hypercoagulability, which predisposes to venous thromboembolism (VTE). We analyzed …

Introduction COVID-19 is associated with an increased thromboembolic risk. However, the
mechanisms triggering clot formation in those patients remain unknown. Patients and …

Severe COVID-19 is frequently associated with thromboembolic complications. Increased
platelet activation and platelet–leukocyte aggregate formation can amplify thrombotic …

Studies of patients with COVID-19 have demonstrated markedly dysregulated coagulation
and a high risk of morbid arterial and venous thrombotic events. Elevated levels of blood …

Plasma concentrations of extracellular vesicles (EVs) originating from cells involved in
COVID-19-associated coagulopathy (CAC), their longitudinal trend and association with …